Page last updated: 2024-11-11

caffeoylmalic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

caffeoylmalic acid: from extracts of Chelidonium majus & Corydalis lutea [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
CorydalisgenusA plant genus of the family FUMARIACEAE (classified by some in PAPAVERACEAE) that contains isoquinoline alkaloids.[MeSH]PapaveraceaeThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]
ChelidoniumgenusA plant genus in the family PAPAVERACEAE, order Papaverales, subclass Magnoliidae.[MeSH]PapaveraceaeThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]
Chelidonium majusspecies[no description available]PapaveraceaeThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]

Cross-References

ID SourceID
PubMed CID6124299
CHEMBL ID393293
CHEBI ID169040
SCHEMBL ID19894754
MeSH IDM0261871

Synonyms (26)

Synonym
CHEBI:169040
caffeoylmalic acid
2-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxybutanedioic acid
CHEMBL393293
92344-57-5
2-o-(trans-caffeoyl)malic acid
SCHEMBL19894754
2-{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}butanedioic acid
2-o-caffeoylmalic acid
(-)-phaselic acid
phaseolic acid?
(s)-phaselic acid
149197-97-7
Q18379746
2-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)butanedioic acid
butanedioic acid, ((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-
butanedioic acid, 2-(((2e)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)-
8EY7S5QS7D ,
butanedioic acid, 2-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)-
coumaroyl malic acid
2-(((2e)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)butanedioic acid
(e)-2-((3-(3,4-dihydroxyphenyl)acryloyl)oxy)succinic acid
(e)-2-((3-(3,4-dihydroxyphenyl)acryloyl)oxy)succinicacid
unii-8ey7s5qs7d
DTXSID301031926
AKOS040734961
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycinnamic acidAny member of the class of cinnamic acids carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
simplecoumarins biosynthesis620
superpathway of anthocyanin biosynthesis (from pelargonidin 3-O-glucoside)231
salvianin biosynthesis121
shisonin biosynthesis117
superpathway of anthocyanin biosynthesis (from cyanidin and cyanidin 3-O-glucoside)519
phaselate biosynthesis314

Bioassays (11)

Assay IDTitleYearJournalArticle
AID294162Inhibition of diphenolase activity of mushroom tyrosinase at 0.056 mM2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Identification of tyrosinase inhibitors from Marrubium velutinum and Marrubium cylleneum.
AID357272Inhibition of A23187-induced LTB4 formation in human polymorphonuclear leukocytes
AID357271Formation of 15HETE in A-23187-stimulated human polymorphonuclear leukocytes at 1000 uM relative to control
AID357270Formation of 15HETE in A-23187-stimulated human polymorphonuclear leukocytes at 100 uM relative to control
AID357276Inhibition of A23187-induced LTB4 formation in human polymorphonuclear leukocytes at 100 to 1000 uM
AID357289Formation of 15HETE in A-23187-stimulated human polymorphonuclear leukocytes at 10 uM relative to control
AID357278Enhancement of PGE2 formation in A-23187-stimulated human polymorphonuclear leukocytes at 100 to 1000 uM
AID357288Cytotoxicity against human polymorphonuclear leukocytes assessed as occurrence of cell suspension or lactate dehydrogenase release at 1 to 1000 uM
AID357277Inhibition of A23187-induced 5HETE formation in human polymorphonuclear leukocytes at 100 to 1000 uM
AID357273Inhibition of A23187-induced 12-hydroxy-5,8,10-heptadecatrienoic acid formation in human polymorphonuclear leukocytes
AID357274Inhibition of A23187-induced 5HETE formation in human polymorphonuclear leukocytes
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's5 (45.45)29.6817
2010's4 (36.36)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.68 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]